Omvoh®
Understanding Omvoh®
Omvoh® (mirikizumab-mrkz) is a prescription biologic medication developed by Eli Lilly and Company to treat adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). Omvoh® provides a targeted approach for managing inflammatory bowel diseases by inhibiting the IL-23 pathway, addressing the underlying inflammation associated with UC and CD.
How Omvoh® Works:
- Inhibits IL-23, a key inflammatory cytokine
- Reduces inflammation in the digestive tract
- Helps achieve and maintain remission in UC and CD patients
FDA Approvals:
- Ulcerative Colitis (UC): Approved in October 2023 for adults with moderately to severely active UC
- Crohn’s Disease (CD): Approved in January 2025 for adults with moderately to severely active CD
For more information, please visit the Omvoh® patient website and speak with your healthcare provider to determine if Omvoh® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Eli Lilly and Company |
CLASS: Interleukin-23 (IL-23) Inhibitor |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion Induction, then Subcutaneous Injection |
|
FREQUENCY: Infusion Induction Weeks zero, four, and eight, then injection week 12, and every four weeks thereafter |
Length of infusion: About 30 mins |
FOR MORE INFORMATION: |
Related drugs
